Does MEDVi Offer Tirzepatide? Verified Answer, Cost & What to Check First

Does MEDVi offer tirzepatide? The verification matrix

We cross-referenced MEDVi's own bill-of-rights pricing page, MEDVi's GLP-1 program page, MEDVi's terms of service, the FDA Warning Letter database, FDA's April 2026 compounding guidance, the Day v. OpenLoop court docket, and three independent third-party reviewers (US News, ConsumerAffairs, Vaccine Alliance).

What kind of tirzepatide does MEDVi actually offer?

Tirzepatide is a dual GLP-1 and GIP receptor agonist developed by Eli Lilly and approved by the FDA as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023). MEDVi does not sell those brand-name products as its default tirzepatide offering.

MEDVi tirzepatide injection

Uses the same route of administration as brand-name Zepbound and Mounjaro: weekly subcutaneous injection. That's the route the FDA approved for those products. To be precise: the FDA-approved route does not mean a compounded injection has been FDA-reviewed or shown equivalent to the approved product — but it's the same delivery method used in clinical trials and the brand-name approvals. The injection is not part of the active class-action lawsuit.

MEDVi tirzepatide tablets

The harder call. Eli Lilly's public position, stated in an open letter to patients, is that the FDA has only approved tirzepatide for delivery via subcutaneous injection — no regulator has evaluated any oral version of tirzepatide for safety or efficacy. The tablets are the subject of the active class-action lawsuit Day v. OpenLoop Health. They are $70 cheaper at first month, but you're paying less for a product whose ability to deliver therapeutic medication into your bloodstream is being challenged in federal court. We recommend the injection, not the tablets.

How much does MEDVi tirzepatide actually cost?

Verified pricing matrix (last verified April 30, 2026)

Confirm first-month and refill pricing at checkout. A clinician decides whether to prescribe.

Is MEDVi's tirzepatide FDA-approved?

The brand-name path: Eli Lilly manufactures tirzepatide as Mounjaro and Zepbound. These products went through full FDA approval, including the SURMOUNT trial program for Zepbound, where adults without diabetes lost an average of 18% of body weight after 72 weeks at the highest approved dose. That clinical data applies to FDA-approved Zepbound — not to compounded versions.

The compounded path: Compounded tirzepatide is prepared by a state-licensed pharmacy under a patient-specific prescription. It's legal under federal compounding rules, but it's not FDA-approved as a finished product, and the FDA hasn't reviewed compounded GLP-1s for safety, effectiveness, or quality.

We won't claim MEDVi's compounded tirzepatide has the "same active ingredient" as Mounjaro or Zepbound — FDA flagged that exact phrase in MEDVi's marketing in February 2026. If FDA approval is non-negotiable for you, MEDVi isn't your best path. Jump to the Ro / Zepbound section below →

The damaging admission you should hear before going further

But here's the reframe: because MEDVi skips the brand-name path, it can offer tirzepatide at $349 listed first-month instead of $1,000+/month at retail for brand-name Zepbound without insurance. For a cash-pay buyer who can't access brand-name Zepbound through insurance and would otherwise be priced out of GLP-1 therapy entirely, that gap is the entire reason this market exists.

The trade you're making is regulatory rigor for affordability and access. That trade is legitimate for some people and not for others. We'd rather you make it with eyes open.

Is MEDVi a legit company?

The FDA warning letter (Feb 20, 2026)

MEDVi was one of 30 telehealth companies the FDA warned in the same enforcement push for similar marketing violations on compounded GLP-1s. The specific issues: product labels suggesting MEDVi was the manufacturer (it isn't — its partner pharmacies are), and "same active ingredient as Mounjaro/Zepbound" language that implied FDA approval that compounded products don't have. The FDA did not find any medication contamination, dosing errors, or patient harm. MEDVi continues to operate.

The class action (filed Nov 2025, Day v. OpenLoop Health)

The plaintiff law firm is challenging compounded oral tirzepatide tablets sold across a network of telehealth storefronts, including MEDVi. The core allegation: there's no validated absorption pathway for oral tirzepatide, since the only FDA-approved oral GLP-1 (Wegovy pill) requires a patented absorption enhancer that compounded oral tirzepatide doesn't have. Eli Lilly itself has publicly stated no regulator has evaluated any oral version of tirzepatide. The injection is not part of this lawsuit — only the tablets. No court has ruled on the merits as of April 30, 2026.

Injection vs tablets — which is the better bet?

If you specifically want oral GLP-1 — needles aren't for everyone — MEDVi is not the cleanest provider for that lane while the tablet litigation is pending. SHED positions oral and sublingual compounded GLP-1 as its core offering rather than a secondary product. We'd send you there to evaluate it on its own terms, separately from this MEDVi decision.

Recommended for the injection format. See alternatives below if you specifically want oral.

Does MEDVi take insurance for tirzepatide?

If insurance coverage or prior-authorization help is essential to your decision, MEDVi is not the right provider for you. Our full MEDVi insurance guide covers this in detail. For insurance support, Ro carries FDA-approved Zepbound, has a dedicated insurance concierge, and offers a free GLP-1 Insurance Coverage Checker.

Does MEDVi prescribe Zepbound or Mounjaro?

MEDVi's GLP-1 program page now lists FDA-approved Wegovy® pill, Wegovy® injection, and Zepbound® injection under a separate $99 membership + medication cost path. Mounjaro is not currently listed on that brand-name path. The default MEDVi tirzepatide programs are compounded.

Don't assume "MEDVi tirzepatide" means brand-name Zepbound. Confirm exactly which product you'd be receiving at checkout. If you want brand-name Zepbound with insurance support, Ro is the cleaner choice — Ro matches LillyDirect / NovoCare pricing, includes prior-authorization help, and offers a free coverage checker.

Where is MEDVi tirzepatide available?

Per ConsumerAffairs reporting, MEDVi operates in 49 states (every U.S. state except North Dakota).

State rules can change. Verify your specific state and format at MEDVi's checkout flow before paying.

What real MEDVi tirzepatide patients actually report

Testimonials are from public review platforms. We have an affiliate relationship with MEDVi; quotes are not independently verified. Testimonials are not evidence of medication safety or effectiveness. Individual results vary and are not typical.

Who is MEDVi tirzepatide right for — and who isn't?

How to get started with MEDVi tirzepatide (the actual process)

MEDVi's intake is a short online questionnaire, followed by clinician review through OpenLoop Health. Shipping/tracking generally appears within two business days; prescription typically arrives within eight to nine days from checkout and approval.

1. Complete MEDVi's online questionnaire — medical history, current medications, weight goals. Be honest.
2. Independent OpenLoop Health clinician review. An OpenLoop clinician meets with you after checkout to determine whether you qualify. Payment doesn't override the clinician.
3. In live-visit-required states (Kansas, Indiana, Mississippi, New Mexico, Oklahoma, West Virginia), you'll be scheduled for a video or phone consultation before prescription.
4. If approved, prescription routes to one of three partner pharmacies — Triad Rx (Daphne, AL), RedRock Pharmacy (St. George, UT), or Beaker Pharmacy & Compounding (McKinney, TX). You don't get to pick.
5. Medication ships in cold packs (the injection requires refrigeration).
6. Ongoing care is unlimited messaging with your assigned clinical team and monthly check-ins.

Switching from MEDVi semaglutide to tirzepatide — what to ask

Yes, you can request to switch from MEDVi compounded semaglutide to compounded tirzepatide. Whether the clinician approves the switch is a medical decision. Tirzepatide is priced higher than semaglutide ($349 vs $179 first-month for injection per ConsumerAffairs reporting). Your titration may reset to a starting tirzepatide dose.

Ask your assigned clinician (not customer service) these questions:

1. Is tirzepatide medically appropriate given my current response, side effects, and goals?
2. Will I start at a beginner tirzepatide dose, or will my dose carry over equivalently?
3. How will the cost change for me specifically — first month, refill, dose tiers?
4. Will my current refill date roll over, or does switching reset the billing cycle?
5. Will the same partner pharmacy fill it, or will it route to a different one?
6. What side effects should I watch for during the transition that I wasn't seeing on semaglutide?

See our MEDVi tirzepatide vs semaglutide comparison for a full breakdown.

What to ask MEDVi before you pay (the 10-question checklist)

The most important verification step is getting MEDVi to confirm — in writing or via a checkout screenshot — the exact formulation, pharmacy, state availability, first-month price, refill price, dose-tier pricing, refund terms, and cancellation timing.

1. Is the medication compounded tirzepatide, or am I being routed to brand-name?
2. Is it injection, tablet, or oral/sublingual?
3. Which pharmacy will fill my prescription — Triad Rx, RedRock, or Beaker?
4. Is that pharmacy licensed to ship to my state?
5. Is the format I want available in my state for my profile?
6. What is the exact first-month price I'll see at checkout?
7. What is the exact refill price after the first month?
8. Does the price change as my dose titrates up?
9. What happens to my charge if the clinician decides not to prescribe?
10. What's the cancellation deadline relative to my next billing date, and how exactly do I cancel?

Bottom line — should you use MEDVi for tirzepatide?

Use MEDVi compounded tirzepatide injection if you're a cash-pay buyer who can't access or afford brand-name Zepbound, you've read the FDA warning letter and class-action context above and made an informed choice, you're in a state MEDVi serves, and you're willing to verify exact pricing and terms at checkout.

Skip MEDVi if you require FDA-approved medication (route to Ro), want oral GLP-1 specifically (route to SHED), need insurance support (route to Ro), or aren't sure yet (take the quiz).

Frequently Asked Questions